GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Total Liabilities

Nanopharmaceutics (Nanopharmaceutics) Total Liabilities : $10.00 Mil (As of Sep. 2018)


View and export this data going back to 2016. Start your Free Trial

What is Nanopharmaceutics Total Liabilities?

Nanopharmaceutics's Total Liabilities for the quarter that ended in Sep. 2018 was $10.00 Mil.

Nanopharmaceutics's quarterly Total Liabilities declined from Mar. 2018 ($10.57 Mil) to Jun. 2018 ($10.24 Mil) and declined from Jun. 2018 ($10.24 Mil) to Sep. 2018 ($10.00 Mil).

Nanopharmaceutics's annual Total Liabilities increased from Dec. 2015 ($0.01 Mil) to Dec. 2016 ($8.34 Mil) and increased from Dec. 2016 ($8.34 Mil) to Dec. 2017 ($9.63 Mil).

Nanopharmaceutics Total Liabilities Historical Data

The historical data trend for Nanopharmaceutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanopharmaceutics Total Liabilities Chart

Nanopharmaceutics Annual Data
Trend Dec15 Dec16 Dec17
Total Liabilities
0.01 8.34 9.63

Nanopharmaceutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.03 9.63 10.57 10.24 10.00

Nanopharmaceutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nanopharmaceutics's Total Liabilities for the fiscal year that ended in Dec. 2017 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.619+(0.009+-0.0009999999999991
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=9.63

Total Liabilities=Total Assets (A: Dec. 2017 )-Total Equity (A: Dec. 2017 )
=0.666--8.961
=9.63

Nanopharmaceutics's Total Liabilities for the quarter that ended in Sep. 2018 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.998+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=10.00

Total Liabilities=Total Assets (Q: Sep. 2018 )-Total Equity (Q: Sep. 2018 )
=0.714--9.284
=10.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanopharmaceutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nanopharmaceutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanopharmaceutics (Nanopharmaceutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » Total Liabilities
Comparable Companies
MIII TSE:5363 TSE:7721 TSE:5821 TSX:AEF SDOIA DFM:GGICO SAU:2120 ABWN COL:RICH.N0000 CNAC MIL:SPRT XSGO:QUEMCHI TSE:3353 COL:VONE.N0000 XPAE:APIC MIL:CRS ELEC ATH:MIG XCNQ:MARI
Traded in Other Exchanges
N/A
Address
14120 NW 126 Terrace, Alachua, FL, USA, 32615
Website
https://www.nanopharmaceutics.com
Nanopharmaceutics Inc is a clinical-stage specialty pharmaceutical company. It is engaged in developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company's pipeline products include Triapine, Ammonium Tetrathiomolybdate, and Aza-TdC targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3 targeting CNS; and Ramoplanin and NanoDOX.